mSASSS in the X-ray completer cohort randomised to secukinumab at baseline
| Variable | Secukinumab intravenous 150 mg | Secukinumab intravenous 75 mg | Secukinumab pooled |
|---|---|---|---|
| Overall population | |||
| Patients (n) | 86 | 82 | 168 |
| Baseline | 9.63 (16.63) | 10.84 (16.69) | 10.22 (16.62) |
| Change at week 104 | 0.30 (1.94) | 0.31 (3.04) | 0.30 (2.53) |
| Patients with syndesmophytes at baseline | |||
| Patients (n) | 51 | 53 | 104 |
| Baseline | 16.12 (19.09) | 16.69 (18.32) | 16.41 (18.61) |
| Change at week 104 | 0.49 (2.50) | 0.45 (3.77) | 0.47 (3.20) |
| Patients without syndesmophytes at baseline | |||
| Patients (n) | 35 | 29 | 64 |
| Baseline | 0.17 (0.56) | 0.16 (0.40) | 0.16 (0.49) |
| Change at week 104 | 0.01 (0.19) | 0.03 (0.33) | 0.02 (0.26) |
| Elevated hsCRP | |||
| Patients (n) | 55 | 50 | 105 |
| Baseline | 11.57 (17.69) | 14.22 (19.16) | 12.83 (18.36) |
| Change at week 104 | 0.48 (2.25) | 0.46 (3.08) | 0.47 (2.66) |
| Normal hsCRP | |||
| Patients (n) | 31 | 32 | 63 |
| Baseline | 6.18 (14.19) | 5.56 (10.04) | 5.87 (12.16) |
| Change at week 104 | –0.03 (1.16) | 0.06 (3.00) | 0.02 (2.27) |
| Male | |||
| Patients (n) | 63 | 60 | 123 |
| Baseline | 11.91 (18.57) | 13.70 (18.44) | 12.78 (18.45) |
| Change at week 104 | 0.19 (2.01) | 0.58 (3.44) | 0.38 (2.79) |
| Female | |||
| Patients (n) | 23 | 22 | 45 |
| Baseline | 3.39 (6.44) | 3.05 (5.68) | 3.22 (6.02) |
| Change at week 104 | 0.59 (1.73) | –0.46 (1.23) | 0.08 (1.58) |
| Smokers (at baseline) | |||
| Patients (n) | 25 | 17 | 42 |
| Baseline | 13.10 (19.45) | 10.88 (9.20) | 12.20 (16.00) |
| Change at week 104 | −0.18 (1.71) | 1.56 (4.00) | 0.52 (2.95) |
| Non-smokers (at baseline) | |||
| Patients (n) | 61 | 65 | 126 |
| Baseline | 8.21 (15.28) | 10.83 (18.21) | 9.56 (16.84) |
| Change at week 104 | 0.49 (2.00) | –0.02 (2.67) | 0.23 (2.38) |
n indicates number of patients with evaluable paired X-ray data at both baseline and week 104 (X-ray completers). Data shown as mean (SD). mSASSS ranges from 0 to 72, with higher scores indicating greater radiographic damage. Patients received 10 mg/kg secukinumab at baseline and weeks 2 and 4, before receiving indicated dose of secukinumab subcutaneously every four weeks from week 8.
hsCRP, high-sensitivity C-reactive protein; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score.